Literature DB >> 24021585

High proportions of CD4⁺ T cells among residual bone marrow T cells in childhood acute lymphoblastic leukemia are associated with favorable early responses.

Imke Lustfeld1, Bianca Altvater, Martina Ahlmann, Sandra Ligges, Peter Brinkrolf, Annegret Rosemann, Anja Moericke, Claudia Rossig.   

Abstract

Residual nonmalignant T cells in the bone marrow of patients with acute leukemias may be involved in active immune responses to leukemic cells. Here, we investigated the phenotypic signature of T cells present at diagnosis in 39 pediatric patients with acute lymphoblastic leukemia (ALL) treated within standardized ALL-BFM study protocols. Previously described age associations of lymphocyte subpopulations in the peripheral blood of healthy children were reproduced in leukemic bone marrow. Analysis of individual lymphocyte parameters and risk-associated variables using univariate linear regression models revealed a correlation of higher CD4/CD8 ratios at diagnosis with a favorable bone marrow response on day 15. Separate analysis of CD4⁺ cells with the CD4⁺CD25(hi)FoxP3⁺ T(reg) cell phenotype showed that the association was caused by non-T(reg) CD4⁺ cells. The association of higher CD4/CD8 ratios with a favorable bone marrow response on day 15 of treatment persisted in a cohort extended to 69 patients. We conclude that CD4⁺ non-T(reg) cells in leukemic bone marrow at diagnosis may have a role in early response to treatment. Prospective analysis of the CD4/CD8 ratio in a large cohort of pediatric patients is now needed. Moreover, future experiments will establish the functional role of the individual T cell subsets in immune control in pediatric ALL.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24021585     DOI: 10.1159/000351429

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  6 in total

1.  Developmental exposure to 2,3,7,8 tetrachlorodibenzo-p-dioxin attenuates later-life Notch1-mediated T cell development and leukemogenesis.

Authors:  Lori S Ahrenhoerster; Tess C Leuthner; Everett R Tate; Peter A Lakatos; Michael D Laiosa
Journal:  Toxicol Appl Pharmacol       Date:  2015-01-10       Impact factor: 4.219

2.  Residual Bone Marrow T & NK-Cells at Diagnosis in Pediatric Pre-B-ALL: A Case-Control Study.

Authors:  Dalia Mahmoud Eldewi; Hanan A El-Hagrasy; Rasha Mahmoud Gouda; Mohammed Abd El Malik Hassan; Shimaa Moustafa Kamel; Naglaa F Abd El Haliem; Haneya A A Anani
Journal:  Int J Gen Med       Date:  2022-08-07

Review 3.  The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia.

Authors:  Erica Dander; Chiara Palmi; Giovanna D'Amico; Giovanni Cazzaniga
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 4.  T Cell Subsets During Early Life and Their Implication in the Treatment of Childhood Acute Lymphoblastic Leukemia.

Authors:  Shanie Saghafian-Hedengren; Eva Sverremark-Ekström; Anna Nilsson
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561

5.  Non-tumour bone marrow lymphocytes correlate with improved overall survival in childhood acute lymphoblastic leukaemia.

Authors:  Claire Edwin; Joanne Dean; Laura Bonnett; Kate Phillips; Russell Keenan
Journal:  Pediatr Blood Cancer       Date:  2016-06-27       Impact factor: 3.167

6.  CD4+CD25highCD127low/-FoxP3+ Regulatory T Cell Subpopulations in the Bone Marrow and Peripheral Blood of Children with ALL: Brief Report.

Authors:  M Niedźwiecki; O Budziło; M Zieliński; E Adamkiewicz-Drożyńska; L Maciejka-Kembłowska; T Szczepański; P Trzonkowski
Journal:  J Immunol Res       Date:  2018-05-29       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.